0001209191-20-054245.txt : 20201007
0001209191-20-054245.hdr.sgml : 20201007
20201007205721
ACCESSION NUMBER: 0001209191-20-054245
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201005
FILED AS OF DATE: 20201007
DATE AS OF CHANGE: 20201007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DOBMEIER ERIC
CENTRAL INDEX KEY: 0001202785
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 201229955
MAIL ADDRESS:
STREET 1: C/O SAETTLE GENETICS INC
STREET 2: 21823 30TH DRIVE SE
CITY: BOTHELL
STATE: WA
ZIP: 98021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ADURO BIOTECH, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
BUSINESS PHONE: 510-848-4400
MAIL ADDRESS:
STREET 1: 740 HEINZ AVENUE
CITY: BERKELEY
STATE: CA
ZIP: 94710
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-10-05
0
0001435049
ADURO BIOTECH, INC.
KDNY
0001202785
DOBMEIER ERIC
C/O CHINOOK THERAPEUTICS, INC.
1600 FAIRVIEW AVE. E.
SEATTLE
WA
98102
1
1
0
0
President, CEO
Common Stock
2020-10-05
4
A
0
46337
A
46337
D
Stock Option (right to buy)
0.35
2020-10-05
4
A
0
463358
A
2029-06-05
Common Stock
463358
463358
D
Stock Option (right to buy)
0.42
2020-10-05
4
A
0
423555
A
2030-03-17
Common Stock
423555
423555
D
Stock Option (right to buy)
14.77
2020-10-06
4
A
0
271647
0.00
A
2030-10-05
Common Stock
271647
271647
D
Restricted Stock (RSU) (Common Stock)
2020-10-06
4
A
0
92389
0.00
A
2030-10-05
Common Stock
92389
92389
D
Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met.
The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with the merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer.
The stock option vested as to 25% of the total shares on April 1, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Received in connection with the merger of Private Chinook into the Issuer (the "Merger") in exchange for a stock option to acquire 1,585,822 shares of Private Chinook common stock for $0.10 per share.
The stock option vests as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Received in connection with the Merger in exchange for a stock option to acquire 1,449,600 shares of Private Chinook common stock for $0.12 per share.
The stock option vests as to 25% of the total shares on October 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement.
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
/s/ Kirk Schumacher, Attorney-in-Fact
2020-10-07